Re2O Frequently Asked Questions

Re2O is made from donated human dermal tissue that is processed to remove donor cells, resulting in human acellular dermal matrix (hADM). This material is then refined into very fine particles using L&C Bio’s proprietary micronisation technique, which is designed to preserve the matrix’s structural features throughout the process.

The resulting material contains components of the extracellular matrix (ECM)—the natural structural framework that surrounds cells in human tissue.

ECM stands for extracellular matrix. Think of it as the natural support network surrounding the cells in your skin.

It contains proteins such as collagen, elastin, fibronectin, laminin and tenascin, alongside other components such as proteoglycans and hyaluronic acid. Together, these help give skin its structure, strength, elasticity and hydration.

Beyond providing physical support, the ECM also helps regulate cell behaviour, creating an environment in which cells live, communicate and function.

Re2O is manufactured by L&C Bio, an AATB-accredited tissue bank, using donated human dermal tissue sourced from tissue banks accredited by the Association for Advancing Tissue and Biologics (AATB). Donors undergo screening, testing and eligibility assessment, and the donated tissue is processed in compliance with applicable Good Tissue Practice (GTP) requirements and L&C Bio’s established safety and quality procedures to produce human acellular dermal matrix (hADM).

No. Re2O is an acellular tissue material made from donated human dermal tissue that has been processed to remove donor cells while retaining components of the extracellular matrix (ECM)—the natural support framework surrounding cells in human tissue. It provides tissue-derived matrix material rather than living donor cells.

The aim of decellularisation is to remove cellular material while retaining components of the tissue’s extracellular matrix.

The remaining matrix contains structural components naturally found within human dermal ECM. The exact composition of a processed tissue material depends on the source tissue and the manufacturer’s processing methods.

Turning donated tissue into an acellular matrix involves several processing steps. Manufacturers may use different methods to remove donor cells and unwanted material, preserve ECM components, and prepare the final injectable product.

These differences can influence the finished product’s composition, structural properties and safety profile. For this reason, the manufacturing process, quality controls and testing of the final material are important considerations when evaluating an ECM product.

No.

Products can differ in their source material, processing methods, particle characteristics, composition, residual cellular material and quality-control specifications.

For this reason, products should be assessed based on their own manufacturing information and supporting data rather than assuming that findings from one ECM product automatically apply to another.

In the context of an ECM product, purity refers to the extent to which the intended extracellular matrix components are retained while unwanted material—such as donor cells, cellular debris and processing residues—is removed.

Safety measures can include reviewing donor medical and social history, screening and testing for transmissible infections, tissue processing and quality-control testing.

The risk of disease transmission from screened and processed donated human tissue is considered very low. Donors undergo medical-history review and infectious-disease screening and testing, while the donated tissue undergoes controlled processing, sterilisation and quality checks.

Re2O is manufactured by L&C Bio, a company with established experience in processing human acellular dermal matrix (hADM). Its human ADM materials have also been used in medical and reconstructive applications, providing a broader safety track record for the manufacturer’s tissue-processing technology.

For Re2O specifically, L&C Bio has stated that donor screening, sterile management and full tissue traceability are part of its safety system, with testing conducted at multiple stages. As of April 2026, the company reported that there had been no reports of serious side effects since Re2O's launch.

Different injectable products support the skin in different ways.

Hyaluronic acid (HA) is a naturally occurring component of the extracellular matrix (ECM) that attracts and retains water. HA injectables are commonly used to improve hydration or provide volume, depending on their formulation.

Collagen biostimulators, such as PLLA and PDLLA, encourage the skin’s own cells to produce collagen through tissue responses involving immune-cell signalling and remodelling. Their mechanisms vary and are more complex in nature.

Collagen-based injectables directly introduce collagen, which is one component of the ECM. Their effects depend on the formulation and should not automatically be described as stimulating the production of the entire ECM.

Re2O introduces tissue-derived ECM components through micronised human acellular dermal matrix (hADM), including collagen, elastin and proteoglycans. It can therefore be described as directly supplying ECM components, rather than relying solely on the skin to produce new collagen.

Your doctor can advise which approach may be appropriate for your skin and treatment goals.

Re2O is not considered a filler. Re2O is used as an ECM skin booster to deliver tissue-derived extracellular matrix components into the skin. The treatment aims to improve skin texture and support the skin’s structural and microenvironment, which plays a role in how cells live, communicate and function.

Different injectable products have different intended uses, properties and injection techniques. Your doctor should explain what Re2O is being used for in your individual treatment and what kind of result can realistically be expected.

Yes. When considering a relatively new injectable treatment, it is important to distinguish between research on acellular dermal matrices (ADMs) generally, studies involving L&C Bio’s other ADM products, and evidence specifically studying Re2O.

L&C Bio’s ADM products, including MegaDerm and MegaDerm Plus, have been evaluated in published clinical studies involving breast reconstruction, reconstruction following parotid surgery, and skin grafting. These studies provide background on the use of the manufacturer’s dermal matrices in tissue reconstruction.

Re2O itself has been investigated in the paper titled “Injectable Particulated Human Acellular Dermal Matrix Booster for Skin Restoration: An Integrated Randomized, Split-Face, Double-Blinded Clinical Trial and Preclinical Study.” The study combined a controlled clinical trial with laboratory investigations and reported promising clinical and biological findings consistent with dermal remodelling.

Together, these publications provide a foundation for understanding L&C Bio’s ADM technology and emerging evidence for Re2O.

Acellular dermal matrices have been used in medicine for more than 30 years, and more than 1000 scientific and clinical publications. Initially for severe burn injuries and later in reconstructive surgery. This provides an established background for ADM technology

A qualified doctor should assess your skin, medical history, allergies, medications and treatment goals to determine whether Re2O is suitable for you.

Tell your doctor if you are pregnant or breastfeeding, have an autoimmune condition, are taking medicines that affect your immune system or blood clotting, have significant allergies, or have an active infection or inflammation around the proposed treatment area.

Re2O is administered by injection by a qualified medical practitioner.

You may experience stinging, pressure or discomfort during treatment. The experience can vary depending on the treatment area and injection technique. Your doctor can explain the procedure and any options available to make treatment more comfortable.

Temporary injection-site effects can include redness, swelling, tenderness, bruising or small bumps.

As with other injectable procedures, complications such as infection, persistent swelling or lumps and other injection-related problems may also occur. Your doctor should explain the relevant risks, expected recovery, aftercare and warning signs that require medical attention.

Improvements after Re2O treatment may develop gradually rather than appear immediately. Changes may become more noticeable over the first three to four weeks, although the timing and degree of improvement vary depending on your skin condition, treatment area, injection technique and treatment plan.

Your doctor should explain what you can realistically expect, as individual results cannot be guaranteed.

How long the results last varies from person to person and depends on several factors, including your initial skin condition, overall skin health and lifestyle.

Your doctor can explain the available evidence and help you understand what duration of improvement you can reasonably expect.

There is no universal treatment schedule.

The number and the interval between sessions should be determined by your doctor based on your skin concerns, medical suitability, treatment goals and response to treatment. More treatment does not necessarily mean a better result.

Re2O may be incorporated into a broader treatment plan alongside other aesthetic procedures, depending on your individual skin needs and treatment goals.

Your doctor can advise which treatments may complement each other and recommend the appropriate timing and sequence to achieve your desired outcome safely.

Avoid comparing products based on a single headline number or marketing claim.

Consider the source of the material, manufacturing and decellularisation process, quality-control testing, what laboratory measurements actually represent, evidence relating to the specific product, and the experience of the treating doctor.

Most importantly, ask your doctor to explain why a particular product is appropriate for you.